American Well (AMWL) Stock Overview
An enterprise platform and software company, delivers digitally enabling hybrid care in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
AMWL Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
American Well Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.83 |
| 52 Week High | US$9.83 |
| 52 Week Low | US$3.71 |
| Beta | 1.53 |
| 1 Month Change | 60.62% |
| 3 Month Change | 90.87% |
| 1 Year Change | 49.39% |
| 3 Year Change | -80.34% |
| 5 Year Change | -96.38% |
| Change since IPO | -97.87% |
Recent News & Updates
Narrative Update • May 22
AMWL: Updated Telehealth Margins And Revenue Trends Will Shape Balanced 2026 Outlook
Analysts have lifted their price target on American Well to $7.50 from $6.25, citing updated assumptions around fair value, discount rate, revenue trends, profit margins, and future P/E multiples reflected in recent Street research. Analyst Commentary Bullish Takeaways Bullish analysts point to the higher US$7.50 price target as better aligning with updated fair value assumptions, suggesting that prior models may have been too conservative on how the business is valued.Narrative Update • May 02
AMWL: Updated Profitability Assumptions And Telehealth Execution Will Shape Balanced 2026 Outlook
Analysts have trimmed their price targets on American Well by $1 to $2, citing updated assumptions around profitability and a revised future P/E outlook as key reasons for the change. Analyst Commentary Recent price target revisions on American Well reflect analysts recalibrating their expectations on profitability and future P/E assumptions, rather than a fundamental shift in how they view the business model.Recent updates
Narrative Update • May 22
AMWL: Updated Telehealth Margins And Revenue Trends Will Shape Balanced 2026 Outlook
Analysts have lifted their price target on American Well to $7.50 from $6.25, citing updated assumptions around fair value, discount rate, revenue trends, profit margins, and future P/E multiples reflected in recent Street research. Analyst Commentary Bullish Takeaways Bullish analysts point to the higher US$7.50 price target as better aligning with updated fair value assumptions, suggesting that prior models may have been too conservative on how the business is valued.Narrative Update • May 02
AMWL: Updated Profitability Assumptions And Telehealth Execution Will Shape Balanced 2026 Outlook
Analysts have trimmed their price targets on American Well by $1 to $2, citing updated assumptions around profitability and a revised future P/E outlook as key reasons for the change. Analyst Commentary Recent price target revisions on American Well reflect analysts recalibrating their expectations on profitability and future P/E assumptions, rather than a fundamental shift in how they view the business model.
Narrative Update • Apr 18
AMWL: Refined Discount And P E Assumptions Will Support Future Re Rating Potential
Analysts have trimmed their price targets on American Well by $1 to $2, citing updated assumptions around discount rates, revenue growth expectations, profit margins, and future P/E. These changes keep fair value estimates broadly in line with prior views.Narrative Update • Apr 04
AMWL: Rebased Assumptions Will Support Future Earnings Re Rating Potential
Analysts have reduced their price targets on American Well by $1 to $2, citing revised assumptions on discount rates, revenue trends, profit margins and future P/E as the main drivers behind the change. Analyst Commentary Recent research updates point to more cautious assumptions on discount rates, revenue trends, profit margins and future P/E multiples for American Well.Narrative Update • Mar 20
AMWL: Extended Elevance Agreement Will Support Future Earnings Re Rating Potential
Analysts have trimmed their price targets on American Well after recent cuts of $2 and $1. These changes have contributed to a reset in expectations as analysts factor in softer revenue growth assumptions, a slightly higher discount rate, and a higher future P/E multiple in their models.
Narrative Update • Mar 06
AMWL: Slower Profit Progress And Contract Risks Will Pressure Future Margin Upside
Analysts have trimmed their price target on American Well from $6.00 to $5.00, reflecting updated views on fair value, discount rate, revenue trends, profit expectations, and future P/E multiples after recent research updates from the Street. Analyst Commentary Recent Street research has highlighted a more cautious tone around American Well, with multiple bearish analysts trimming their price targets.Narrative Update • Feb 20
AMWL: Cost Discipline And Extended Elevance Agreement Will Shape Balanced 2026 Outlook
The analyst price target for American Well has been reduced by $1.88, from $8.13 to $6.25. Analysts cite softer revenue growth assumptions, slightly lower profit margin expectations, and a modestly lower future P/E multiple, as reflected in recent target cuts at firms including TD Cowen and Stifel.Narrative Update • Feb 06
AMWL: Extended Elevance Health Partnership Will Support Cash Flow Breakeven Upside Potential
Analysts have maintained their price target for American Well at $9.00, citing only minor adjustments to assumptions around discount rate, revenue growth, profit margin and future P/E that do not materially change their overall view. What's in the News On December 24, 2025, American Well extended its Master Services Agreement with Elevance Health, with a new term starting January 1, 2026 and running through January 1, 2029, followed by automatic one-year renewals unless either party ends the deal under the contract terms (Key Developments).Narrative Update • Jan 22
AMWL: 2026 Cash Flow Breakeven Goal Will Support Future Margin Upside
Analysts have trimmed their price target on American Well to US$7 from US$10, citing the recent 3Q adjusted EBITDA beat, guidance raise, and reiterated 2026 cash flow breakeven goal as key reasons for the updated view. Analyst Commentary Bearish analysts trimming the price target to US$7 from US$10 are sending a clear message that, even with the 3Q adjusted EBITDA beat and guidance update, they still see a balance of risks that caps near term upside.Narrative Update • Jan 08
AMWL: Cost Controls And 2026 Cash Flow Breakeven Will Support Upside Potential
Narrative Update on American Well Analysts have trimmed their fair value estimate for American Well from US$12.00 to US$9.00, aligning price targets with a higher discount rate, more cautious revenue growth and margin assumptions, and recent Street research that highlights both cost reduction progress and a revised US$7 price target from US$10. Analyst Commentary Bullish analysts are highlighting that, despite a lower headline price target, the revised US$7 level is still above the current fair value estimate of US$9.00.Analysis Article • Jan 06
American Well Corporation (NYSE:AMWL) Shares Fly 30% But Investors Aren't Buying For Growth
American Well Corporation ( NYSE:AMWL ) shareholders are no doubt pleased to see that the share price has bounced 30...Narrative Update • Dec 25
AMWL: Cash Flow Breakeven Progress Will Underpin Future Margin Expansion
Analysts have trimmed their price target on American Well, cutting it by $3 to $7, as they factor in slightly weaker growth and margin assumptions despite acknowledging progress toward the company's 2026 cash flow breakeven goals. Analyst Commentary Bearish analysts are tempering enthusiasm around American Well, arguing that the recent adjustment to a $7 price target more accurately reflects a slower growth trajectory and lingering questions about the pace of margin expansion.Narrative Update • Dec 11
AMWL: Cost Discipline And 2026 Cash Flow Breakeven Will Drive Future Upside
Analysts have trimmed their price target on American Well, cutting it by $3 to $7 per share, as they balance the positive surprise in Q3 adjusted EBITDA and reaffirmed 2026 cash flow breakeven goals against slightly more conservative assumptions for the discount rate, revenue growth, and future valuation multiples. Analyst Commentary Bullish Takeaways Bullish analysts highlight the Q3 adjusted EBITDA beat as evidence that cost reduction initiatives are gaining traction faster than previously modeled, supporting a path to improved profitability.Narrative Update • Nov 26
AMWL: Cost Reduction Progress And Cash Flow Breakeven Will Support Future Upside
Narrative Update on American Well Analysts have lowered their price target for American Well from $10 to $7. They cited ongoing cost reduction efforts and progress toward cash flow breakeven as positive factors, even as expectations for revenue growth and margins have softened.Narrative Update • Nov 10
AMWL: Cost Reduction Initiatives And 2026 Cash Flow Goals Will Drive Upside
Analysts have revised their price target for American Well from $10.00 to $7.00. They cite ongoing cost reduction efforts and a maintained outlook for 2026 cash flow breakeven as factors influencing the updated assessment.Analysis Article • Nov 06
Investors Don't See Light At End Of American Well Corporation's (NYSE:AMWL) Tunnel And Push Stock Down 27%
To the annoyance of some shareholders, American Well Corporation ( NYSE:AMWL ) shares are down a considerable 27% in...Analysis Article • Nov 06
Lacklustre Performance Is Driving American Well Corporation's (NYSE:AMWL) 27% Price Drop
To the annoyance of some shareholders, American Well Corporation ( NYSE:AMWL ) shares are down a considerable 27% in...Seeking Alpha • Oct 08
American Well: Trading At Half Of Net Cash, It Has Optionality
Summary American Well Corporation offers telehealth SaaS and provider services. It remains deeply unprofitable, losing over 90% of its value since IPO. AWML trades at roughly half its net cash, providing downside protection and speculative upside, though profitability remains unlikely without significant changes. Despite guiding for adjusted EBITDA breakeven in 2026, AWML continues to burn cash and shows little evidence of scalable revenue growth or margin improvement. I initiate with a Hold rating: AWML is unattractive for long-term investment but may appeal to speculators due to its net cash position and optionality. Read the full article on Seeking AlphaNarrative Update • Aug 08
Digital Platforms And AI Will Reshape Future Healthcare
American Well’s valuation has weakened as its Future P/E increased and Net Profit Margin declined, justifying a stagnant analyst price target at $9.50. What's in the News Amwell, as part of a Leidos-led partnership, was awarded an extension of its Digital First contract to support the Military Health System (MHS), serving about 9.6 million beneficiaries.Analysis Article • Jun 27
Revenues Working Against American Well Corporation's (NYSE:AMWL) Share Price
With a price-to-sales (or "P/S") ratio of 0.5x American Well Corporation ( NYSE:AMWL ) may be sending very bullish...
New Narrative • Apr 04
I Expect Military Health System Deployment Will Optimize Subscription Services
The expansion of Amwell's platform in the Military Health System is expected to boost subscription revenue and enhance margins significantly.Analysis Article • Dec 17
Is American Well (NYSE:AMWL) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Analysis Article • Oct 09
Market Might Still Lack Some Conviction On American Well Corporation (NYSE:AMWL) Even After 25% Share Price Boost
Despite an already strong run, American Well Corporation ( NYSE:AMWL ) shares have been powering on, with a gain of 25...Analysis Article • Jul 24
Even With A 26% Surge, Cautious Investors Are Not Rewarding American Well Corporation's (NYSE:AMWL) Performance Completely
Those holding American Well Corporation ( NYSE:AMWL ) shares would be relieved that the share price has rebounded 26...Analysis Article • Jun 26
Here's Why We're Watching American Well's (NYSE:AMWL) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Analysis Article • May 30
It's Down 31% But American Well Corporation (NYSE:AMWL) Could Be Riskier Than It Looks
Unfortunately for some shareholders, the American Well Corporation ( NYSE:AMWL ) share price has dived 31% in the last...Analysis Article • May 04
American Well Corporation (NYSE:AMWL) Just Released Its First-Quarter Earnings: Here's What Analysts Think
Investors in American Well Corporation ( NYSE:AMWL ) had a good week, as its shares rose 8.0% to close at US$0.57...Analysis Article • Apr 02
Not Many Are Piling Into American Well Corporation (NYSE:AMWL) Stock Yet As It Plummets 27%
Unfortunately for some shareholders, the American Well Corporation ( NYSE:AMWL ) share price has dived 27% in the last...Analysis Article • Mar 19
Is American Well (NYSE:AMWL) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. For example, although...Analysis Article • Dec 25
American Well Corporation's (NYSE:AMWL) Share Price Not Quite Adding Up
There wouldn't be many who think American Well Corporation's ( NYSE:AMWL ) price-to-sales (or "P/S") ratio of 1.6x is...Analysis Article • Nov 28
Will American Well (NYSE:AMWL) Spend Its Cash Wisely?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Seeking Alpha • Nov 08
Amwell Looks To 2024 For Stabilization But Operating Losses Remain High
Summary American Well Corporation recently reported its Q3 2023 financial results, with a continued poor showing. The firm provides a telemedicine platform to healthcare system participants. Revenue continues to drop and operating losses remain extremely high, so my outlook on American Well Corporation is Bearish [Sell]. Read the full article on Seeking AlphaShareholder Returns
| AMWL | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | 23.5% | 7.8% | 1.6% |
| 1Y | 49.4% | -40.5% | 28.2% |
Return vs Industry: AMWL exceeded the US Healthcare Services industry which returned -40.5% over the past year.
Return vs Market: AMWL exceeded the US Market which returned 28.2% over the past year.
Price Volatility
| AMWL volatility | |
|---|---|
| AMWL Average Weekly Movement | 9.5% |
| Healthcare Services Industry Average Movement | 10.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AMWL has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: AMWL's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 562 | Ido Schoenberg | business.amwell.com |
American Well Corporation, an enterprise platform and software company, delivers digitally enabling hybrid care in the United States and internationally. The company offers Amwell Platform, a cloud-based enablement platform, digitally enables a scalable healthcare experience across all care settings; Amwell Carepoint, a device enable healthcare providers to leverage proprietary carts and transform existing tablets and TVs into digital access points in clinical settings; Amwell Converge, a platform and wraparound services of digital care into the in-person, automated, and virtual care settings; and Behavioral Health, a platform that offer students and faculty the right level of care. It also provides specialty care programs, including dermatology, musculoskeletal care, second opinion, and cardiometabolic care for patients and members; Amwell Medical Group network services consisting of primary and urgent care, behavioral health therapy, lactation counseling, and nutrition services.
American Well Corporation Fundamentals Summary
| AMWL fundamental statistics | |
|---|---|
| Market cap | US$164.24m |
| Earnings (TTM) | -US$87.88m |
| Revenue (TTM) | US$237.38m |
0.7x
P/S Ratio-1.9x
P/E RatioIs AMWL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AMWL income statement (TTM) | |
|---|---|
| Revenue | US$237.38m |
| Cost of Revenue | US$109.68m |
| Gross Profit | US$127.70m |
| Other Expenses | US$215.58m |
| Earnings | -US$87.88m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.26 |
| Gross Margin | 53.80% |
| Net Profit Margin | -37.02% |
| Debt/Equity Ratio | 0% |
How did AMWL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/01 14:06 |
| End of Day Share Price | 2026/05/29 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
American Well Corporation is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ravi Misra | Berenberg |
| Allen Lutz | BofA Global Research |
| David Larsen | BTIG |